GenVec Inc  

(Public, NASDAQ:GNVC)   Watch this stock  
Find more results for GNVC
0.00 (0.00%)
Oct 6 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.61 - 4.67
Open     -
Vol / Avg. 0.00/30,730.00
Mkt cap 36.27M
P/E     -
Div/yield     -
EPS -0.20
Shares 17.27M
Beta 1.76
Inst. own 33%
Nov 10, 2015
Q3 2015 GenVec Inc Earnings Release (Estimated) Add to calendar
Oct 23, 2015
GenVec Inc Annual Shareholders Meeting (Estimated) - 8:30AM EDT - Add to calendar
Aug 7, 2015
Q2 2015 GenVec Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -1471.65% -41.63%
Operating margin -1476.38% -42.00%
EBITD margin - -38.35%
Return on average assets -57.96% -22.00%
Return on average equity -67.32% -28.09%
Employees 11 -
CDP Score - -


910 Clopper Rd Ste 220n
United States - Map
+1-240-6320740 (Phone)
+1-240-6320735 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. The Company develops and commercializes its product candidates through collaborations. In collaboration with Novartis, the Company's hearing and balance disorders program is involved in the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. In the area of animal health, the Company, with its collaborators, is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

Officers and directors

Wayne T. Hockmeyer Ph.D. Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Douglas J. Swirsky President, Chief Executive Officer, Corporate Secretary, Director
Age: 45
Bio & Compensation  - Reuters
James V. Lambert Chief Financial Officer, Chief Accounting Officer, Senior Director, Controller, Treasurer
Age: 50
Bio & Compensation  - Reuters
Bryan T. Butman Ph.D. Senior Vice President - Development
Age: 62
Bio & Compensation  - Reuters
Douglas E. Brough Ph.D. Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Stefan D. Loren Ph.D. Director
Age: 51
Bio & Compensation  - Reuters
Quinterol J. Mallette M.D. Director
Age: 41
Bio & Compensation  - Reuters
Michael S. Richman Director
Age: 54
Bio & Compensation  - Reuters
William N. Kelley M.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Marc R. Schneebaum Independent Director
Age: 60
Bio & Compensation  - Reuters